Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer ended Tuesday’s session lower, then steadied in extended trading as investors digested a late-day safety headline tied to its hemophilia medicine Hympavzi.

Pfizer Inc. ended Thursday’s session essentially flat and stayed steady in after-hours trading, a sign that investors are still digesting the company’s newly issued 2026 outlook while watching a fast-evolving U.S. policy backdrop around drug pricing.

Pfizer, Inc. is back in focus on Monday, December 15, 2025, with investors weighing fresh collaboration news, a looming guidance event, and a familiar debate: is Pfizer stock a high-yield value play with a rebuilding pipeline—or a “wait-and-see” story facing years of patent headwinds?

From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance. Notably, PFE is trading below its 200-day moving average, indicating lingering bearish momentumtrefis.com. On the upside, a decisive push above the $27–$28 level would be a bullish signal that the stock’s trend is turning. In the near term, the stock has managed to climb back above its 50-day moving averageinvesting.com, a positive sign, and appears to have technical support in the mid-$24 areachartmill.com. Chart indicators are mixed: Pfizer’s RSI sits around 48, smack in neutral territorychartmill.com, and its MACD momentum indicator is slightly negativechartmill.com. This suggests the stock is neither overbought nor oversold at current levels, but hasn’t yet gathered strong upward momentum. Traders may watch $23–$24 as a support zone – if PFE falls below that, it could retest the year’s low near $21. Conversely, $27 is key resistance – a breakout above that could open the door to the low-$30s. In summary, Pfizer’s chart is still repairing: the